202 related articles for article (PubMed ID: 38232611)
1. Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?
Benvenuti C; Laot L; Grinda T; Lambertini M; Pistilli B; Grynberg M
ESMO Open; 2024 Feb; 9(2):102228. PubMed ID: 38232611
[TBL] [Abstract][Full Text] [Related]
2. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis.
Arecco L; Blondeaux E; Bruzzone M; Ceppi M; Latocca MM; Marrocco C; Boutros A; Spagnolo F; Razeti MG; Favero D; Spinaci S; Condorelli M; Massarotti C; Goldrat O; Del Mastro L; Demeestere I; Lambertini M
Hum Reprod; 2022 May; 37(5):954-968. PubMed ID: 35220429
[TBL] [Abstract][Full Text] [Related]
3. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.
Letourneau JM; Sinha N; Wald K; Harris E; Quinn M; Imbar T; Mok-Lin E; Chien AJ; Rosen M
Hum Reprod; 2017 Oct; 32(10):2123-2129. PubMed ID: 28938748
[TBL] [Abstract][Full Text] [Related]
4. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review.
Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA
Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
7. Controlled ovarian stimulation outcomes of fertility preservation procedures in newly diagnosed breast cancer patients: a retrospective study from a single-tertiary-IVF centre.
Sahin G; Goker ENT; Gokmen E; Yeniay L; Acet F; Zekioglu O; Tavmergen E
J Obstet Gynaecol; 2022 Apr; 42(3):518-523. PubMed ID: 34382483
[TBL] [Abstract][Full Text] [Related]
8. Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer.
Pereira N; Kligman I; Hunt R; Kopparam R; Wahmann B; Rosenwaks Z
Gynecol Endocrinol; 2019 Mar; 35(3):214-216. PubMed ID: 30403906
[TBL] [Abstract][Full Text] [Related]
9. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients.
Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I
Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617
[TBL] [Abstract][Full Text] [Related]
10. Oocyte vitrification for fertility preservation following COS does not delay the initiation of neoadjuvant chemotherapy for breast cancer compared to IVM.
Sellami I; Mayeur A; Benoit A; Zeghari F; Peigné M; Roufael J; Grynberg M; Sonigo C
J Assist Reprod Genet; 2023 Mar; 40(3):473-480. PubMed ID: 36752941
[TBL] [Abstract][Full Text] [Related]
11. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
Letourneau JM; Wald K; Sinha N; Juarez-Hernandez F; Harris E; Cedars MI; McCulloch CE; Dolezal M; Chien AJ; Rosen MP
Cancer; 2020 Feb; 126(3):487-495. PubMed ID: 31639215
[TBL] [Abstract][Full Text] [Related]
12. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series.
Russo M; Liu K; Chan C
Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.
Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B
Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489
[TBL] [Abstract][Full Text] [Related]
14. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
Azim AA; Costantini-Ferrando M; Oktay K
J Clin Oncol; 2008 Jun; 26(16):2630-5. PubMed ID: 18509175
[TBL] [Abstract][Full Text] [Related]
15. Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy.
Danis RB; Pereira N; Elias RT
Curr Pharm Biotechnol; 2017 Nov; 18(8):609-613. PubMed ID: 28786354
[TBL] [Abstract][Full Text] [Related]
16. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
17. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†.
Pereira N; Hancock K; Cordeiro CN; Lekovich JP; Schattman GL; Rosenwaks Z
Gynecol Endocrinol; 2016 Oct; 32(10):823-826. PubMed ID: 27114051
[TBL] [Abstract][Full Text] [Related]
19. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation.
Cakmak H; Katz A; Cedars MI; Rosen MP
Fertil Steril; 2013 Dec; 100(6):1673-80. PubMed ID: 23987516
[TBL] [Abstract][Full Text] [Related]
20. Time from referral to ovarian tissue cryopreservation in a cohort of Danish women.
Kristensen SG; Pors SE; Poulsen LC; Andersen ST; Wakimoto Y; Yding Andersen C
Acta Obstet Gynecol Scand; 2019 May; 98(5):616-624. PubMed ID: 30758835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
